A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
ConditionMultiple Myeloma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorJanssen Research & Development, LLC
About this trial
The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called relapsed if it comes back after treatment and is called 'refractory' if does not respond to treatment) who have received at least 3 prior lines of therapy.
Eligibility criteria
Qualifiers
MM diagnosis according to the international myeloma working group (IMWG) diagnostic criteria
Measurable disease at screening as assessed by central laboratory
Received at least 3 prior lines of antimyeloma therapy including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-cluster of differentiation (CD) 38 monoclonal antibody (mAb)
Documented evidence of progressive disease(PD) or failure to achieve a response to the last line of therapy based on investigator's determination of response by the IMWG criteria
Disqualifiers
None
Trial design
Treatments tested in this trial
- JNJ-79635322
Treatment groups
157 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov